Atlas Trials

Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis

Clinical trial NCT05383742 · RECRUITING

Trial details

NCT number
NCT05383742
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Tuberculous Meningitis
Start date
2023-12-07
Primary completion
2028-04-30
Enrollment
330

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.